DENVER, July 10 /PRNewswire/ -- Cochlear Americas announced today that the U.S. Food and Drug Administration (FDA) has cleared the Cochlear(TM) Baha(R) BP100 Sound Processor, the industry's first programmable bone conduction hearing solution. The Baha BP100 is an excellent choice for many children and adults with conductive hearing loss, mixed hearing loss or single-sided sensorineural deafness.
The Baha BP100 improves upon previous systems by offering users the industry's first bone- anchored hearing solution with advanced automatic digital signal processing. The automatic signal processing functions automatically adapt to the user's sound environment, helping to provide greater audibility and listening comfort across different listening environments. Adults are now able to transition easily to different listening environments without degradation in hearing performance. Parents enjoy greater peace of mind knowing that their child can participate all day in various daily activities, without interruption, and with greater access to speech and sounds.
"The Baha BP100 is the most advanced implantable bone conduction solution available, representing a major technological leap forward in sound processor utility and design. It's engineered to deliver better hearing performance than ever before," said Chris Smith, President of Cochlear Americas. "Users who cannot benefit from hearing aids now have the best opportunity to connect to sound and effectively communicate."
The Baha BP100 was redesigned based on feedback from recipients, parents, and clinicians, resulting in a device that is sophisticated yet easy to use. It incorporates features especially designed for children including tamper-resistant battery doors, a key lock function, and a titanium and plastic casing for maximum durability. The device is designed to be more water protected than ever before, allowing children and adults to live full, active lives.
'/>"/>
| SOURCE Cochlear Americas Copyright©2009 PR Newswire. All rights reserved |